Academic Journal

Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis

التفاصيل البيبلوغرافية
العنوان: Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis
المؤلفون: Aya Takahashi, Michihisa Moriguchi, Yuya Seko, Toshihide Shima, Yasuhide Mitsumoto, Hidetaka Takashima, Hiroyuki Kimura, Hideki Fujii, Hiroki Ishikawa, Takaharu Yo, Hiroshi Ishiba, Atsuhiro Morita, Masayasu Jo, Yasuyuki Nagao, Masahiro Arai, Tasuku Hara, Akira Okajima, Akira Muramatsu, Naomi Yoshinami, Tomoki Nakajima, Hironori Mitsuyoshi, Atsushi Umemura, Taichiro Nishikawa, Kanji Yamaguchi, Takeshi Okanoue, Yoshito Itoh
المصدر: Cancers; Volume 12; Issue 3; Pages: 754
بيانات النشر: Multidisciplinary Digital Publishing Institute
سنة النشر: 2020
المجموعة: MDPI Open Access Publishing
مصطلحات موضوعية: hepatocellular carcinoma, lenvatinib, early tumor shrinkage, overall survival, Response Evaluation Criteria in Solid Tumors (RECIST)
الوصف: We investigated the association between early tumor shrinkage (ETS) and treatment outcome in patients with hepatocellular carcinoma treated with lenvatinib (LEN). A retrospective analysis was performed in 104 patients. ETS was defined as tumor shrinkage at the first evaluation in the sum of target lesions’ longest diameters from baseline according to the Response Evaluation Criteria in Solid Tumors (RECIST). The median overall survival (OS) was not reached, whereas the median progression-free survival (PFS) was 5.0 months. The receiver operating characteristic curve analysis in differentiating long-term responders (PFS ≥ 5.0 months) from short-term responders (PFS < 5.0 months) revealed an ETS cut-off value of 10%. ETS ≥ 10% was significantly correlated with better PFS and OS compared with ETS < 10%. Additionally, ETS ≥ 10% showed a better discrimination ability on prognosis compared with modified RECIST-based objective response at the first evaluation. Multivariate analysis confirmed ETS ≥ 10% as an independent predictor of better OS, as well as a Child–Pugh score of 5 and macrovascular invasion. In conclusion, ETS ≥ 10% was strongly associated with outcome in patients treated with LEN. This biomarker could allow earlier assessment of the treatment response and guide treatment decision-making for HCC.
نوع الوثيقة: text
وصف الملف: application/pdf
اللغة: English
Relation: Cancer Therapy; https://dx.doi.org/10.3390/cancers12030754
DOI: 10.3390/cancers12030754
الاتاحة: https://doi.org/10.3390/cancers12030754
Rights: https://creativecommons.org/licenses/by/4.0/
رقم الانضمام: edsbas.1D85B092
قاعدة البيانات: BASE